Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
Alector Inc (Nasdaq: ALEC) announced presentations on its TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®). The event will be held online and in Philadelphia from July 28 to August 1, 2024.
Key presentations include:
- Two posters on the AL002 TREM2 program, developed with AbbVie, focusing on the INVOKE-2 phase 2 study in early Alzheimer's disease.
- Three posters on progranulin programs (latozinemab and AL101/GSK4527226), developed with GSK, covering plasma biomarkers, the PROGRESS-AD phase 2 study, and genetics related to Alzheimer's disease.
These presentations highlight Alector's ongoing efforts in immuno-neurology and Alzheimer's disease research.
Alector Inc (Nasdaq: ALEC) ha annunciato la presentazione dei suoi programmi TREM2 e progranulina alla prossima Conferenza Internazionale dell'Associazione Alzheimer® 2024 (AAIC®). L'evento si terrà online e a Philadelphia dal 28 luglio al 1 agosto 2024.
Le presentazioni chiave includono:
- Due poster sul programma AL002 TREM2, sviluppato con AbbVie, incentrato sullo studio di fase 2 INVOKE-2 per l'Alzheimer precoce.
- Tre poster sui programmi di progranulina (latozinemab e AL101/GSK4527226), sviluppati con GSK, che coprono biomarcatori plasmatici, lo studio di fase 2 PROGRESS-AD e la genetica relativa alla malattia di Alzheimer.
Queste presentazioni mettono in evidenza gli sforzi continui di Alector nella neuroimmunologia e nella ricerca sulla malattia di Alzheimer.
Alector Inc (Nasdaq: ALEC) anunció presentaciones sobre sus programas de TREM2 y progranulina en la próxima Conferencia Internacional de la Asociación de Alzheimer® 2024 (AAIC®). El evento se llevará a cabo en línea y en Filadelfia del 28 de julio al 1 de agosto de 2024.
Las presentaciones clave incluyen:
- Dos carteles sobre el programa AL002 TREM2, desarrollado con AbbVie, centrándose en el estudio de fase 2 INVOKE-2 en la enfermedad de Alzheimer temprana.
- Tres carteles sobre programas de progranulina (latozinemab y AL101/GSK4527226), desarrollados con GSK, que cubren biomarcadores plasmáticos, el estudio de fase 2 PROGRESS-AD y la genética relacionada con la enfermedad de Alzheimer.
Estas presentaciones destacan los esfuerzos continuos de Alector en la neuroinmunología y la investigación de la enfermedad de Alzheimer.
Alector Inc (Nasdaq: ALEC)는 다가오는 2024년 알츠하이머 협회 국제 회의 (AAIC®)에서 TREM2 및 프로그라누린 프로그램에 대한 발표를 발표했습니다. 이 행사는 2024년 7월 28일부터 8월 1일까지 필라델피아와 온라인에서 열릴 예정입니다.
주요 발표 내용은 다음과 같습니다:
- 조기 알츠하이머 질환에 대한 INVOKE-2 2상 연구에 초점을 맞춘 AL002 TREM2 프로그램에 대한 두 개의 포스터, AbbVie와 공동 개발했습니다.
- 혈장 바이오마커, PROGRESS-AD 2상 연구 및 알츠하이머 질환과 관련된 유전학을 다루는 프로그라누린 프로그램 (latozinemab 및 AL101/GSK4527226)에 대한 세 개의 포스터, GSK와 공동 개발했습니다.
이 발표들은 Alector의 면역신경학 및 알츠하이머 질환 연구에서의 지속적인 노력을 강조합니다.
Alector Inc (Nasdaq: ALEC) a annoncé des présentations sur ses programmes TREM2 et progranuline lors de la prochaine Conférence Internationale de l'Association Alzheimer® 2024 (AAIC®). L'événement se déroulera en ligne et à Philadelphie du 28 juillet au 1 août 2024.
Les présentations clés comprennent :
- Deux affiches sur le programme AL002 TREM2, développé avec AbbVie, axées sur l'étude de phase 2 INVOKE-2 pour la maladie d'Alzheimer précoce.
- Trois affiches sur les programmes de progranuline (latozinemab et AL101/GSK4527226), développés avec GSK, couvrant les biomarqueurs plasmatiques, l'étude de phase 2 PROGRESS-AD et la génétique liée à la maladie d'Alzheimer.
Ces présentations mettent en lumière les efforts continus d'Alector en neuro-immunologie et en recherche sur la maladie d'Alzheimer.
Alector Inc (Nasdaq: ALEC) gab bekannt, dass es Präsentationen zu seinen TREM2- und Progranulin-Programmen auf der kommenden Internationalen Alzheimer-Vereinigungskonferenz® 2024 (AAIC®) geben wird. Die Veranstaltung findet vom 28. Juli bis 1. August 2024 online und in Philadelphia statt.
Wichtige Präsentationen umfassen:
- Zwei Poster zum AL002 TREM2-Programm, das in Zusammenarbeit mit AbbVie entwickelt wurde und sich auf die INVOKE-2-Studie der Phase 2 bei früher Alzheimer-Krankheit konzentriert.
- Drei Poster zu Progranulin-Programmen (latozinemab und AL101/GSK4527226), die mit GSK entwickelt wurden und Plasma-Biomarker, die PROGRESS-AD-Studie der Phase 2 und genetische Aspekte im Zusammenhang mit der Alzheimer-Krankheit abdecken.
Diese Präsentationen heben Alectors fortlaufende Bemühungen in der Immunneurologie und der Alzheimerforschung hervor.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024.
Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET.
AL002 Presentations
TREM2 Program (AL002) is Being Developed in Collaboration with AbbVie
Poster Title: Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95594)
Presenting Author: Arthur J. Mayorga, Ph.D., Vice President, Clinical Development Neurology, Alector
Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET
Poster Title: Use of a blood-based amyloid test for screening in INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95646)
Presenting Author: Brady Burgess, Ph.D., Staff Scientist, Alector
Session Date and Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m. ET
Progranulin Presentations
Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226) are Being Developed in Collaboration with GSK
Poster Title: Using plasma biomarkers to distinguish TDP43 associated pathologies (#89291)
Presenting Author: Gopi Ganji, Ph.D., Scientific Leader, GSK
Session Date and Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m. ET
Poster Title: PROGRESS-AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti-sortilin monoclonal antibody, in patients with early Alzheimer's disease (#90247)
Presenting Author: Christine Bailey, Ph.D., Clinical Development Director, GSK
Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET
Poster Topic: Genetics, progranulin, and Alzheimer’s disease (#89497)
Presenting Author: Chun-Fand Xu, Ph.D., Senior Director, Human Genetics Senior Director, GSK
Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com
FAQ
What is Alector presenting at AAIC 2024?
When and where is AAIC 2024 being held?
What is the INVOKE-2 study mentioned in Alector's AAIC 2024 presentations?
Which companies is Alector (ALEC) collaborating with for its presented programs?
What is the PROGRESS-AD study mentioned in Alector's AAIC 2024 presentations?
